Immix Biopharma Completes NEXICART-2 Enrollment, Topline Results Expected in Q3
Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In addition to meeting guidance for NEXICART-2 enrollment completion and announcing topline NEXICART-2 results expected Q3 2026, Immix has onboarded chief medical officer, Richard Graydon. Graydon is a board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck (MRK).
